keyword
MENU ▼
Read by QxMD icon Read
search

interferon therapy in hepatitis C

keyword
https://www.readbyqxmd.com/read/28901852/recent-advancement-of-direct-acting-antiviral-agents-daas-in-hepatitis-c-therapy
#1
Debasis Das, Mayank Pandya
Hepatitis C virus (HCV) infection is a major health burden worldwide. Approximately, 170-200 million individuals are chronically infected worldwide and a quarter of these patients are at increased risk of developing liver cirrhosis, hepatocellular carcinoma and even liver failure. A complete eradication of the virus is one of the most important treatment goal for antiviral research. In 2011, the first-generation protease inhibitors boceprevir (BOC) telaprevir (TVR) have been approved by FDA as the direct-acting antiviral agents...
September 12, 2017: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/28895871/type-i-interferons-in-the-pathogenesis-and-treatment-of-canine-diseases
#2
REVIEW
Daniela Klotz, Wolfgang Baumgärtner, Ingo Gerhauser
Type I interferons (IFNs) such as IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω represent cytokines, which are deeply involved in the regulation and activation of innate and adaptive immune responses. They possess strong antiviral, antiproliferative, and immunomodulatory activities allowing their use in the therapy of different viral diseases, neoplasms, and immune-mediated disorders, respectively. Initially, treatment strategies were based on nonspecific inducers of type I IFNs, which were soon replaced by different recombinant proteins...
September 2017: Veterinary Immunology and Immunopathology
https://www.readbyqxmd.com/read/28892235/beclabuvir-in-combination-with-asunaprevir-and-daclatasvir-for-hepatitis-c-virus-genotype-1-infection-a-systematic-review-and-meta-analysis
#3
Ali Mahmoud Ahmed, Mohamed Fahmy Doheim, Omar Mohamed Mattar, Nourin Ali Sherif, Duy Hieu Truong, Pham Thi Le Hoa, Kenji Hirayama, Nguyen Tien Huy
Daclatasvir, asunaprevir, and beclabuvir are direct-acting antivirals for patients with hepatitis C virus genotype 1 infection. This systematic review and meta-analysis investigating the efficacy and safety of this three-drug combination in HCV genotype 1 infection. Eleven electronic search engines were searched for relevant publications. Studies were screened for eligibility and data was extracted. The outcomes were pooled as event rate and risk ratio. The protocol was registered in PROSPERO (CRD42017054391)...
September 11, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28888558/elimination-of-hepatitis-c-virus-infection-among-pwid-the-beginning-of-a-new-era-of-interferon-free-daa-therapy
#4
EDITORIAL
Jason Grebely, Julie Bruneau, Philip Bruggmann, Magdalena Harris, Matthew Hickman, Tim Rhodes, Carla Treloar
No abstract text is available yet for this article.
September 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28887750/direct-acting-antiviral-therapy-for-chronic-hcv-infection-results-in-liver-stiffness-regression-over-12%C3%A2-months-post-treatment
#5
Justin Chan, Neliswa Gogela, Hui Zheng, Sara Lammert, Tokunbo Ajayi, Zachary Fricker, Arthur Y Kim, Gregory K Robbins, Raymond T Chung
BACKGROUND: Liver fibrosis stage determines risk of morbidity and mortality from chronic hepatitis C virus (HCV) infection. Prior data have shown long-term reversal of liver fibrosis, measured by vibration-controlled transient elastography (VCTE), in patients successfully treated with interferon-based therapies. AIM: Our study sought to determine the effect of treatment with modern HCV direct-acting antiviral (DAA) therapy on noninvasive liver fibrosis measurements...
September 8, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28884320/direct-acting-antivirals-decreased-tumor-recurrence-after-initial-treatment-of-hepatitis-c-virus-related-hepatocellular-carcinoma
#6
Kenji Ikeda, Yusuke Kawamura, Masahiro Kobayashi, Yoko Kominami, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada
BACKGROUND: Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular carcinoma (HCC). PATIENTS AND METHODS: A total of 177 patients received DAA after curative manners of HCC: 89 patients underwent DAA therapy after initial HCC treatment, and the other 88 patients after repeated therapy of 2-10 times. Among a cohort of HCC patients with surgery and radiofrequency ablation, 89 patients were chosen adjusting age, gender, and Barcelona Clinic Liver Cancer (BCLC) staging with 89 patients with initial HCC therapy...
September 7, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28883690/direct-acting-antiviral-agents-against-hepatitis-c-virus-and-lipid-metabolism
#7
EDITORIAL
Tatsuo Kanda, Mitsuhiko Moriyama
Hepatitis C virus (HCV) infection induces steatosis and is accompanied by multiple metabolic alterations including hyperuricemia, reversible hypocholesterolemia and insulin resistance. Total cholesterol, low-density lipoprotein-cholesterol and triglyceride levels are increased by peginterferon and ribavirin combination therapy when a sustained virologic response (SVR) is achieved in patients with HCV. Steatosis is significantly more common in patients with HCV genotype 3 but interferon-free regimens are not always effective for treating HCV genotype 3 infections...
August 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28879707/analysis-of-hepatitis-c-virus-ns5a-region-in-patients-with-cirrhosis-using-an-ultra-deep-pyrosequencing-method
#8
Fahriye Keskin, Sevgi Ciftci, Filiz Akyuz, Neslihan Abaci, Aris Cakiris, Umit Akyuz, Kadir Demir, Fatih Besisik, Duran Ustek, Sabahattin Kaymakoglu
BACKGROUND: HCV (Hepatitis C Virus) is genetically more diverse than HBV and HIV (Human Immunodeficiency Virus) and exists as quasispecies within infected individuals. This is due to the lack of efficient proofreading of the viral RNA-dependent RNA polymerase. Consequently, quasispecies emerge depending on the mutation rate of the viral polymerase, which may display a high level of genetic variability in a population. In infected individuals, HCV replicates and circulates as quasispecies composed of a complex mixture of different but closely related genomes that undergoes continuous change due to competitive selection and cooperation between arising mutants...
September 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28878911/severe-autoimmune-hemolytic-anemia-during-pegylated-interferon-plus-ribavirin-treatment-for-chronic-hepatitis-c-a-case-report
#9
Shasha Wang, Eryun Qin, Yixiao Zhi, Rui Hua
We report a rare case of severe autoimmune hemolytic anemia triggered by pegylated interferon during combination therapy for chronic HCV. This case demonstrated that interferon can de novo induce autoimmune hemolytic anemia during therapy for chronic hepatitis C in a previously healthy patient.
September 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28877190/regional-differences-in-treatment-rates-for-patients-with-chronic-hepatitis-c-infection-systematic-review-and-meta-analysis
#10
Philip Vutien, Michelle Jin, Michael H Le, Pauline Nguyen, Sam Trinh, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang, Mindie H Nguyen
BACKGROUND & AIMS: Treatment rates with interferon-based therapies for chronic hepatitis C have been low. Our aim was to perform a systematic review of available data to estimate the rates and barriers for antiviral therapy for chronic hepatitis C. METHODS: We conducted a systematic review and meta-analysis searching MEDLINE, SCOPUS through March 2016 and abstracts from recent major liver meetings for primary literature with available hepatitis C treatment rates...
2017: PloS One
https://www.readbyqxmd.com/read/28877177/an-in-vitro-diagnostic-certified-point-of-care-single-nucleotide-test-for-il28b-polymorphisms
#11
Darragh Duffy, Estelle Mottez, Shaun Ainsworth, Tan-Phuc Buivan, Aurelie Baudin, Muriel Vray, Ben Reed, Arnaud Fontanet, Alexandra Rohel, Ventzislava Petrov-Sanchez, Laurent Abel, Ioannis Theodorou, Gino Miele, Stanislas Pol, Matthew L Albert
Numerous genetic polymorphisms have been identified as associated with disease or treatment outcome, but the routine implementation of genotyping into actionable medical care remains limited. Point-of-care (PoC) technologies enable rapid and real-time treatment decisions, with great potential for extending molecular diagnostic approaches to settings with limited medical infrastructure (e.g., CLIA certified diagnostic laboratories). With respect to resource-limited settings, there is a need for simple devices to implement biomarker guided treatment strategies...
2017: PloS One
https://www.readbyqxmd.com/read/28874853/editorial-direct-antiviral-agents-eliminate-the-age-barrier-to-treatment-of-chronic-hepatitis-c
#12
EDITORIAL
Raymond S Koff
Interferon-based therapy for chronic hepatitis C in elderly patients, who are at greatest risk for advanced disease, resulted in low sustained virologic response rates, poor tolerability, a significant frequency of adverse events leading to treatment discontinuation, and the occasional precipitation of hepatic decompensation. In contrast, in the era of direct-acting antiviral therapy, age is no longer a predictor of response rates in those with or without cirrhosis and adverse events are much less frequent...
September 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28873225/chronic-hepatitis-c-increases-the-risk-of-chronic-kidney-disease-ckd-while-effective-hcv-treatment-decreases-the-incidence-of-ckd
#13
Haesuk Park, Chao Chen, Wei Wang, Linda Henry, Robert L Cook, David R Nelson
We aimed to assess the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV) infected patients and the incidence reduction of CKD after receipt of HCV treatment. We also evaluated the risk of membranoproliferative glomerulonephritis (MPGN) and cryoglobulinemia in chronic HCV patients. A retrospective cohort analysis of the Truven Health MarketScan Database (2008-2015) in the United States was conducted. In a cohort of 56,448 HCV-infected patients and propensity score (1:3) matched 169,344 non-HCV patients, we examined the association of HCV infection with the incidence of CKD...
September 5, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28867970/occurrence-and-recurrence-of-hepatocellular-carcinoma-after-successful-direct-acting-antiviral-therapy-for-patients-with-chronic-hepatitis-c-virus-infection
#14
Sirisha Grandhe, Catherine T Frenette
Chronic hepatitis C virus (HCV) infection has generally been associated with a slightly increased risk of developing hepatocellular carcinoma (HCC). For the past several decades, most patients with chronic HCV cirrhosis have been treated with pegylated interferon and ribavirin therapies, which were known to achieve sustained virologic response (SVR) but also carried their own side effects and toxicities. The recent implementation of direct-acting antiviral (DAA) treatments revealed an increased efficacy in difficult-to-treat populations and higher adherence rates given the all-oral nature of the regimens...
July 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28864162/treatment-induced-viral-cure-of-hepatitis-c-virus-infected-patients-involves-a-dynamic-interplay-among-three-important-molecular-players-in-lipid-homeostasis-circulating-microrna-mir-24-mir-223-and-proprotein-convertase-subtilisin-kexin-type-9
#15
Anastasia Hyrina, Andrea D Olmstead, Paul Steven, Mel Krajden, Edward Tam, François Jean
In patients with chronic hepatitis C virus (HCV) infection, viral hijacking of the host-cell biosynthetic pathways is associated with altered lipid metabolism, which contributes to disease progression and may influence antiviral response. We investigated the molecular interplay among four key regulators of lipid homeostasis [microRNA (miR)-122, miR-24, miR-223, and proprotein convertase subtilisin/kexin type 9 (PCSK9)] in HCV-infected patients (n=72) who achieved a treatment-based viral cure after interferon-based therapy with first-generation direct-acting antivirals...
September 2017: EBioMedicine
https://www.readbyqxmd.com/read/28862188/interferon-%C3%AE-inducible-protein-10-in-chronic-hepatitis-c-correlations-with-insulin-resistance-histological-features-sustained-virological-response
#16
Dana Crisan, Mircea Dan Grigorescu, Corina Radu, Alina Suciu, Mircea Grigorescu
BACKGROUND & OBJECTIVES: One of the multiple factors contributing to virological response in chronic hepatitis C (CHC) is interferon-gamma-inducible protein-10 (IP-10). Its level reflects the status of interferon-stimulated genes, which in turn is associated with virological response to antiviral therapy. The aim of this study was to evaluate the role of serum IP-10 levels on sustained virological response (SVR) and the association of this parameter with insulin resistance (IR) and liver histology...
April 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28859226/viral-persistence-liver-disease-and-host-response-in-hepatitis-c-like-virus-rat-model
#17
Sheetal Trivedi, Satyapramod Murthy, Himanshu Sharma, Alex S Hartlage, Arvind Kumar, Sashi Gadi, Peter Simmonds, Lokendra V Chauhan, Troels K H Scheel, Eva Billerbeck, Peter D Burbelo, Charles M Rice, W Ian Lipkin, Kurt Vandergrift, John M Cullen, Amit Kapoor
The lack of a relevant, tractable, and immunocompetent animal model for hepatitis C virus (HCV) has severely impeded investigations of viral persistence, immunity and pathogenesis. In the absence of immunocompetent models with robust HCV infection, homolog hepaciviruses in their natural host could potentially provide useful surrogate models. We isolated a rodent hepacivirus (RHV) from wild rats (Rattus norvegicus), RHV-rn1, acquired the complete viral genome sequence and developed an infectious reverse genetics system...
August 31, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28857900/regression-of-liver-fibrosis-over-a-24-week-period-after-completing-direct-acting-antiviral-therapy-in-patients-with-chronic-hepatitis-c-receiving-care-within-the-national-hepatitis-c-elimination-program-in-georgia-results-of-hepatology-clinic-hepa-experience
#18
Ekaterine Dolmazashvili, Akaki Abutidze, Nikoloz Chkhartishvili, Marine Karchava, Lali Sharvadze, Tengiz Tsertsvadze
OBJECTIVE: We assessed the impact of direct-acting antiviral (DAA) therapy on liver fibrosis regression measured by transient elastography (TE) in patients with chronic hepatitis C virus (HCV) infection. PATIENTS AND METHODS: A prospective cohort study was carried out in HCV monoinfected patients with advanced liver fibrosis or cirrhosis receiving interferon (IFN)-containing or IFN-free DAA therapy. Liver stiffness (LS) score more than 14.5 kPa indicated LS-defined cirrhosis...
August 29, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28856290/recommendations-for-the-treatment-of-hepatitis-c-in-2017
#19
REVIEW
Waldemar Halota, Robert Flisiak, Jacek Juszczyk, Piotr Małkowski, Małgorzata Pawłowska, Krzysztof Simon, Krzysztof Tomasiewicz
The goals of treatment is to eliminate HCV infection, stop or reverse histological changes, reduce the risk of hepatocellular carcinoma development and transmission of the infection to other individuals. According to the recommendation of the Polish Group of Experts for HCV in 2017 all patients with chronic HCV infection should receive treatment, but it is not recommended in patients at high risk of short overall survival. If access to therapy is restricted, priority should be given to patients whose HCV infection can lead to an unfavourable outcome of the disease within a short time frame, particular to individuals with liver cirrhosis, rapidly progressing liver fibrosis, extrahepatic manifestations of HCV infection, chronic kidney diseases, patients before and after organ transplantation...
June 2017: Clin Exp Hepatol
https://www.readbyqxmd.com/read/28856285/association-of-tnf-%C3%AE-and-ccl5-with-response-to-interferon-based-therapy-in-patients-with-hcv-1-genotype
#20
Dzmitry Danilau, Dzmitry Litvinchuk, Nikita Solovey, Olga Krasko, Igor Karpov
AIM OF THE STUDY: To evaluate the role of potential genetic predictors -308G/A TNF-α and -403G/A CCL5 in treatment for HCV 1 genotype. MATERIAL AND METHODS: Treatment results of 130 patients with chronic hepatitis C 1 genotype according to different genotypes of IL28B, CCL5, and TNF-α were analysed using multiple logistic regression. RESULTS: IL28B genotypes CC/CT/TT were found in 27 (20.8%), 74 (56.9%), and 29 (22.3%) patients. Genotypes GG/GA/AA of -308G/A TNF-α were revealed in 98 (75...
March 2017: Clin Exp Hepatol
keyword
keyword
58041
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"